- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07944183
The PRECISION Partners Platform (P3) Study
The PRECISION Partners Platform (P3) Study: a Multi-centre, Multi-sample-type Approach to Establish Alternatives to Sputum Culture for Detecting Lung Infections in Cystic Fibrosis, and Better Understand Host/ Microbe Interactions.
Infections of the lungs are the most common problem for people with Cystic Fibrosis (CF), but also are significant in people with other lung conditions known generally as chronic suppurative lung diseases (CSLD), which can also cause recurrent chest infections. Some of the most common and severe infections are caused by Pseudomonas aeruginosa (Pa), Staphylococcus aureus (Sa), and Aspergillus fumigatus (Af). It is important to detect these early, in order to treat them and prevent damage to the lungs.
At the moment we rely on sputum culture or cough swabs, however, some people (for example small children or those with less severe disease) are not able to provide sputum, and cough swabs are less accurate. Additionally, although modulators such as Kaftrio and Ivacaftor have had significant positive effects on most people with CF taking them, these people often find they no longer produce sputum, and therefore we are not able to test for infections in the same way we did before. Studies have shown that although some people have fewer infections after starting modulators, they generally don't disappear altogether, and therefore we still need a reliable way to test for them.
Furthermore, we have seen that some people react differently to certain infections, and people with more than one infection simultaneously, also respond differently to these infections.
We would like to find new, reliable, easy and acceptable ways of testing for infections that does not require sputum and are acceptable for patients in order to detect, monitor and treat lung infections early. Additionally, we would like to better understand what causes the differing responses patients have to infections, in order to see if there are new ways we can target treatments.
The study is being undertaken in multiple centres across the UK in order to recruit a larger, more diverse and representative group of participants, than we would be able to achieve from one centre alone.
Studieoversikt
Status
Detaljert beskrivelse
This study contributes towards the Cystic Fibrosis Translational Innovation Hub Network in Lung Health and Infection study: PRECISION (PolymicRobial infECtions: bIomarkerS, dIagnOstics & mechaNisms).
Given the difficulties obtaining sputum in the current CF climate (for example, young children, those with less-advanced lung disease, and those on highly effective CFTR modulators), there is a need for alternative means for sampling to detect infections of the lower airway. This study will aim to look at such alternatives including breath analysis (exhaled volatiles), exhaled breath condensate, skin secretions, blood, stool, and urine, but will also further investigate the utility of upper airway samples such as saliva, cough swabs, throat swabs, nasal secretions, and gargles, and compare these to the traditional methods of BAL (when clinically available), and spontaneously expectorated and induced sputum.
Furthermore, current analysis of samples depends on culture, with inherent diagnostic delays which in turn can delay or result in inappropriate treatment as well as increasing the potential for cross infection between patients. There is thus a need for other options to microbial culture, for example PCR, genomics, transcriptomics and 16s gene sequencing, identification of metabolomic and proteomic biomarkers for infection using mass spectrometry and medical detection dogs, all of which have shown promise previously.
Finding reliable alternatives to sputum may also aid in future clinical trial development; currently protocols often require sputum, and thus are limited to patients who can expectorate. Such alternatives may remove this barrier, allowing these patients to benefit from such trials, but also widening the pool of recruitment, having a more accurate representation of the CF community, and thus having more reliable results.
Finally, there is a need to understand the polymicrobial nature of the CF airway, and the impacts different pathogens have on each other or the commensals (in terms of limiting or exacerbating pathogenicity, or encouraging resistance), and on the host. Sample acquisition, and outcomes from this study, will aid the research of other workstreams within the PRECISION group in developing this understanding, which may allow the identification of biomarkers for risk stratification, or targets for future drug development.
Collaboration between multiple sites throughout the UK will result in access to a larger bank of tissue samples, and differing expertise. This will enable an extremely wide breadth of data, impossible to obtain from a single centre alone, to allow us to effectively answer these questions.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Gina Rivellini
- Telefonnummer: 02075947986
- E-post: g.rivellini@imperial.ac.uk
Studer Kontakt Backup
- Navn: Maddy Grassy
- Telefonnummer: 02075947226
- E-post: z.grassy@imperial.ac.uk
Studiesteder
-
-
-
London, Storbritannia, SW3 6LL
- Rekruttering
- Royal Brompton Hospital, part of Guy's and St Thomas' NHS Foundation Trust
-
Ta kontakt med:
- Gemma Wilson
- Telefonnummer: 020 7352 8121
- E-post: g.wilson24@imperial.ac.uk
-
Ta kontakt med:
- Maddy Grassy
- Telefonnummer: +44 20 7594 7226
- E-post: z.grassy@imperial.ac.uk
-
Hovedetterforsker:
- Jane Davies, MBChB, mRcP, MRCPCH, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Males and females with CF, other forms of chronic suppurative lung disease (CSLD) and healthy controls (HC). Selection of patients will be based on their previous clinical microbial culture results.
Beskrivelse
Inclusion Criteria:
- For patients with CF, diagnosis confirmed by standard criteria.
- For patients with other forms of CSLD, a clinical diagnosis of either bronchiectasis (CT scan) or PCD (conventional criteria) will have been confirmed.
- Healthy volunteers will be colleagues and staff contacts (including children) at a participating centre i.e. Royal Brompton Hospital, or will be friends, family or contacts of patients.
- Ability to perform written informed consent (adults only).
Exclusion Criteria:
- Asthma, or any other chronic respiratory disease (only applicable to healthy controls).
- Upper or lower respiratory tract infection symptoms within the previous 4 weeks (applicable only to healthy controls).
- Current smoker/vaper, or ex-smoker/ vaper within the last 10 years (applicable to healthy controls only).
- Inability to understand or cooperate with the test(s)
- Inability to give informed consent, or withdrawal of informed consent (adults only)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: CROSS_SECTIONAL
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
People with Cystic Fibrosis (pwCF)
500 people with Cystic Fibrosis (pwCF) |
|
People with chronic suppurative lung disease (CSLD)
Up to 100 patients with Chronic suppurative lung disease (CSLD) |
|
Healthy control
250 Healthy controls without CF, CSLD or other chronic respiratory disease |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Exploratory outcomes
Tidsramme: From enrollment to year 5
|
Participants will provide at least one of the following samples which will be analysed by culture to determine infection status as per the current gold standards for diagnosis:
The following other samples will be offered to participants (who may choose to perform some, or all, depending on preference):
The results of these analyses will be combined with the gold standard culture results to determine their ability to identify the infection status of that particular individual. The sensitivity and specificity of these sample types and detection techniques to identify particular infections will then be calculated and compared. |
From enrollment to year 5
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Utilising the results of the analyses from the primary outcome
Tidsramme: Enrollment to year 5
|
The results of the analyses from the primary outcome will also be used to better understand the polymicrobial interactions in the Cystic Fibrosis lung, for example, competition between microbes, the changing of one microbe's behaviour in response to another, or protection from host defences, and the impact on health. |
Enrollment to year 5
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Jane Davies, MBChB, mRcP, MRCPCH, MD, Imperial College London
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Ciliopatier
- Genetiske sykdommer, medfødte
- Sykdommer i luftveiene
- Sykdommer i fordøyelsessystemet
- Lungesykdommer
- Spedbarn, nyfødte, sykdommer
- Bronkiale sykdommer
- Pankreassykdommer
- Medfødte abnormiteter
- Otorhinolaryngologiske sykdommer
- Bakterielle infeksjoner
- Bakterielle infeksjoner og mykoser
- Abnormiteter, flere
- Gram-negative bakterielle infeksjoner
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Ciliære motilitetsforstyrrelser
- Infeksjoner
- Cystisk fibrose
- Bronkiektasi
- Pseudomonas-infeksjoner
- Saminfeksjon
Andre studie-ID-numre
- 356585
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Collaboration between multiple sites throughout the UK will result in access to a larger bank of tissue samples, and differing expertise. This will enable an extremely wide breadth of data, impossible to obtain from a single centre alone, to allow us to effectively answer these questions.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .